Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - M&A
 More »

  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... Pharma venture funds and other sources have begun filling the gap left when VCs retrenched on investment, Giovannetti said. M&A activity rises: The total value of mergers and ...
    4-22-2013
  • Clock Ticking in Elan Takeover Battle
    ... saying it expected to complete "due diligence" reviews in 20 days, and noting that its M&A advisors were J.P. Morgan, Bank of America's Merrill Lynch, and Groton. "$1.1+ [billion] ...
    4-3-2013
  • Biopharmas Cooling to Licensing Deals as Patent Cliff Fears Ease
    Also declining last year were M&A deals, which fell to $42.6 billion in 180 deals, or 24% ... One area where licensing and M&A activity could increase this year, Urquhart said, is ...
    3-28-2013
  • Biggest Biotech Trends of 2012
    ... M&A Deals: The Year Without a Blockbuster The year saw no blockbuster like last year's Sanofi $20.1 billion purchase of Genzyme. M&A activity fell 35% over 2011, according to the ...
    1-15-2013
  • Top 25 M&A Deals of 2012
    Whether you jump for joy or quiver in terror at the thought of another M&A, you still want ... shares before the announcement of an M&A deal. #25. YM Biosciences Acquired by: ...
    1-4-2013
  • 7 Biotech Trends for the Coming Year
    ... least a 20% jump in the dollar volume of M&A activity in 2013 compared with 2012, driven ... Deloitte offered another key driver of M&A activity in its 2013 Global Life Sciences ...
    1-3-2013
  • LGC Buys Bioanalytical Sciences Business from Quotient Bioresearch
    This transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site. LGC has been busy with M&A activity lately. Last ...
    1-2-2013
  • Necessary Liaisons: CROs Gain Clout & Responsibility
    ... Is M&A Frenzy Slowing? Many observers say the CRO merger and acquisition activity is ... own company (PharmaNet/i3) is itself an M&A product created to build a CRO with the ...
    1-1-2013
  • Biggest Biotech Trends of 2012
    ... M&A Deals: The Year Without a Blockbuster The year saw no blockbuster like last year's Sanofi $20.1 billion purchase of Genzyme. M&A activity fell 35% over 2011, according to the ...
    12-26-2012
  • Fearing Anchors Away After M&A
    San Diego, Maryland downplay prospect of clusters' last stand. Big pharma's growing M&A ... As some anchors succumb to pharma M&A or their own problems, regions must nurture numerous ...
    8-20-2012
  • Gene Patent Ruling stalls Biotech Rally-Myriad (MYGN) down 4...
    Many biotech stocks hit an 8 year high last week supported by promising clinical data,sales growth, M&A activity and a buzz that positioned biologicals and genomics as the future ...
    8-17-2012
  • The Big Idea for 2009 as Discussed at J.P. Morgan
    Biotech has seen tough times before, but the life science market is now more resilient, buffered by many strong companies, breakthrough technologies, and an M&A theme. And ...
    8-13-2012
  • Will New Appointment "Wax" Healthcare Legislation?
    ... The low productivity of R&D in the drug industry should become a driver for increasing M&A as smaller biotech companies have extensive pipelines, but more difficulty raising ...
    8-13-2012
  • Pharma and Biotech Will Follow the Rest of the Economic Downward...
    Credit ratings have not taken a large hit so far, as virtually all players are saturated with cash. That cash will now, however, not be used to fuel the M&A machines that have been ...
    8-13-2012
  • Roundtable Discussion on Biotech/Pharma Deals
    The panel answered questions such as: What's driving the recent spate of deals, especially all the M&A and partnering activities between pharmaceutical companies and biotech firms? ...
    8-13-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll